The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
30
single dose of 10 mg or 15 mg
Matching placebo
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
RECRUITINGBOLD signal during response inhibition
BOLD signal (brain activity during fMRI, arbitrary units) in the anterior cingulate cortex during response inhibition.
Time frame: Approximately 90 minutes after dose
Glutamate level in the anterior cingulate cortex
Glutamate level (measured by MRS, institutional units) in the anterior cingulate cortex.
Time frame: Approximately 2 hours after dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.